Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Faron Pharmaceuticals Share News (FARN)
FARN Share
Price
FARN Share
News
FARN Share
Chat
FARN Share
Trades15
FARN
Live RNS
FARN Share
Charts
FARN Level 2
Console
FARN Live
Share Price
FARN Broker
Ratings
FARN Directors
Deals
FARN Financial
Diary
FARN
Fundamentals
FARN Short
Positions
FARN
Media
FARN Company
Research
FARN Company
Timeline
Share Price Information for Faron Pharmaceuticals (FARN)
Last checked at -
Last checked at 
Intraday Faron Pharmaceuticals Share Chart
Faron Pharmaceuticals Notes Study Supporting Clevegen Programme
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said an article published in the Journal of Immunology has outlined the functional role of the company's Clever-1 treatment, part of its Clevegen cancer immunotherapy antibody programme.
Faron, which floated in London earlier this month, said the data published in the study supported Clever-1 as an immuosuppresive molecule and supports the use of Clevegen as an immunotherapy product.
"We are working hard to advance our Clevegen programme, as announced recently, towards clinical use as a new onco-immunological alternative," said Faron Chief Executive Markku Jalkanen.
Shares in Faron were trading flat at 275.00 pence on Monday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Latest FARN News
- Faron narrows first-half losses as it advances its lead asset
27 Aug 2025 - UK earnings, trading statements calendar - next 7 days
20 Aug 2025 - Faron secures FDA pathway for lead cancer therapy
18 Aug 2025 - Faron advances development of cancer immunotherapy after FDA feedback
18 Aug 2025 - LONDON MARKET OPEN: Stocks up with eyes on Powell at Jackson Hole
18 Aug 2025 - Faron Pharma hails therapy data on blood cancer ahead of FDA meeting
6 Aug 2025 - AIM WINNERS & LOSERS: CT Automotive to post half-year revenue decline
6 Aug 2025 - LONDON MARKET OPEN: Europe opens higher ahead of construction PMI data
6 Aug 2025
Related News
IN BRIEF: Faron Pharmaceuticals fined EUR30,000 by Nasdaq Helsinki
Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Says the Disciplinary Committee of Nasdaq Helsinki Ltd has imposed an EUR30,0...
WINNERS & LOSERS: James Cropper sees earnings up; Block sells stake
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday.
Faron Pharmaceuticals News
Faron narrows first-half losses as it advances its lead asset
(Sharecast News) - Faron Pharmaceuticals reported a series of first-half clinical and financial milestones on Wednesday, as it advanced its lead asset...
Faron secures FDA pathway for lead cancer therapy
(Sharecast News) - Faron Pharmaceuticals said on Monday that it has secured a clear regulatory pathway for the potential approval of its lead cancer t...
Faron advances development of cancer immunotherapy after FDA feedback
(Alliance News) - Faron Pharmaceuticals Ltd on Monday outlined its plans to further progress its study of an investigational cancer immunotherapy, aft...
LONDON MARKET OPEN: Stocks up with eyes on Powell at Jackson Hole
(Alliance News) - Stock prices in London opened higher on Monday, as investors digest last week's meeting between Donald Trump and Vladimir Putin, and...
Faron Pharma hails therapy data on blood cancer ahead of FDA meeting
(Alliance News) - Faron Pharmaceuticals Ltd on Wednesday announced data for its investigational immunotherapy bexmarilimab, ahead of an upcoming meeti...
AIM WINNERS & LOSERS: CT Automotive to post half-year revenue decline
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Wednesday.
LONDON MARKET OPEN: Europe opens higher ahead of construction PMI data
(Alliance News) - European blue-chips opened in the green on Wednesday, after US stocks retreated on Tuesday ahead of US President Donald Trump's tari...
Follow the stocks
